Virax Biolabs is a biotechnology company focused on T cell immune profiling and diagnostics for viral and immune-mediated diseases. The company specializes in post-acute infection syndromes (PAIS), including conditions like Long COVID, chronic fatigue syndrome, and post-treatment Lyme disease. Virax Biolabs operates two primary platforms. ImmuneSelect is a portfolio of research-use-only reagents, peptide pools, and assays sold to academic institutions, contract research organizations, and biopharmaceutical companies. ViraxImmune is the company's lead development-stage platform intended for clinical diagnostic use to characterize chronic immune dysfunction. Virax Biolabs currently generates revenue from selling ImmuneSelect products through direct sales and distributors. The company aims to commercialize ViraxImmune by first pursuing a laboratory-developed test pathway in the U.S. and subsequently seeking formal regulatory clearance as an in vitro diagnostic. Most of the company's resources are dedicated to research and development to build the clinical evidence required for regulatory submissions. Virax Biolabs maintains laboratory and office space in Glasgow and Shanghai. The company's long-term strategy involves expanding its diagnostic offerings into oncology, transplant medicine, and vaccine response monitoring once it validates its core PAIS applications.